Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.
You may also be interested in...
Quick Commercial Standouts Lacking Among 2016 US Launches
The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Company plans to meet with caregivers and consider other options before moving forward.
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.